Form 4: Alto Neuroscience Reprices Executive Stock Options to Boost Retention and Align Incentives

Alto Neuroscience, Inc. has repriced stock options for its Chief Medical Officer, Adam Savitz, and other continuing employees, lowering the exercise price to $2.35 per share to align with current market value and enhance retention.

Summary

• Alto Neuroscience, Inc. (ANRO) implemented a one-time stock option repricing program, effective July 3, 2025.
• The repricing applies to stock options held by continuing employees with original exercise prices greater than $2.35 per share.
• The exercise price of these repriced options has been reduced to $2.35 per share, which was the closing price of the company's common stock on the repricing date.
• For Adam Savitz, Chief Medical Officer, a total of 328,134 shares across five tranches of employee stock options were repriced.
• Original exercise prices for these options ranged from $4.20 to $14.88 per share, all reduced to the new $2.35 per share exercise price.
• Vesting schedules, expiration dates, and the number of shares underlying the repriced options remain unchanged.
• A one-year retention period applies, requiring employees to pay the original exercise price if repriced options are exercised before this period ends, subject to earlier termination in certain circumstances.

Sentiment

Score: 6

Explanation: The repricing of stock options is a strategic move to retain key talent, particularly the Chief Medical Officer, by restoring the incentive value of their equity awards. While beneficial for employee morale and retention, it could be viewed neutrally or slightly negatively by some shareholders due to the potential for increased future dilution if the stock price recovers and these options are exercised.

Positives

• Enhances employee retention by making stock options more valuable and aligning them with current stock performance, particularly for key personnel.
• Potentially improves employee morale and incentivizes long-term commitment to the company's success.
• For the reporting person, Adam Savitz, the repricing significantly increases the intrinsic value of his stock options, making them more attractive to exercise.

Negatives

• May lead to potential future dilution for existing shareholders if more options are exercised due to the lower exercise prices.
• Could be perceived negatively by some shareholders as it directly benefits employees by reducing their cost to acquire shares, potentially at the expense of broader shareholder value in the short term.
• The one-year retention period, which requires payment of the original exercise price if options are exercised early, could complicate immediate liquidity for employees.

Risks

• Potential for shareholder dissatisfaction if the repricing is viewed as overly dilutive or not sufficiently aligned with the interests of all shareholders.
• Risk of employee turnover if the retention period or other terms of the repricing are not perceived as sufficiently favorable, despite the repricing itself.

Future Outlook

The repricing is intended to incentivize long-term continuous service from key employees by aligning their equity compensation with current market conditions, thereby supporting future company performance.

Management Comments

• The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date").
• The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.
• Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date.

Industry Context

Stock option repricing is a common practice in industries, particularly in biotechnology and pharmaceuticals (where Alto Neuroscience operates), or high-growth technology sectors, when stock prices have fallen significantly below original grant prices. This renders existing options 'underwater' and ineffective as retention tools. Repricing aims to re-motivate employees by restoring the value of their equity incentives and is a recognized strategy to retain key talent during periods of market volatility or company underperformance.

Comparison to Industry Standards

• Stock option repricing is a common strategy employed by companies, particularly in the biotechnology and pharmaceutical sectors, when their stock price has significantly declined, rendering previously granted options 'underwater' (i.e., exercise price is higher than the current market price).
• Companies like Moderna (MRNA) or BioNTech (BNTX) have faced similar challenges with stock volatility impacting employee equity incentives.
• The repricing to the current market price ($2.35) is a standard approach to restore incentive value, similar to actions taken by other companies to retain talent during market downturns or periods of underperformance.
• The inclusion of a one-year retention period, requiring payment of the original exercise price if exercised early, is a common safeguard to ensure continued service and prevent immediate 'flipping' of the repriced options.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if repriced options are exercised; may view the repricing as a necessary retention tool or as a cost.
• Employees (Option Holders): Significant positive impact as their options become more valuable, enhancing motivation and retention.
• Management: Benefits from increased morale and retention of key personnel, supporting long-term strategic goals and operational stability.

Next Steps

• Continued vesting of repriced options based on their original schedules.
• Employees will be subject to a one-year retention period for repriced options, requiring payment of the original exercise price if exercised before the period ends.

Key Dates

Recommendation

Keywords

Alto Neuroscience, ANRO, Stock Option Repricing, SEC Form 4, Executive Compensation, Employee Retention, Equity Compensation, Adam Savitz, Chief Medical Officer, Corporate Governance